A detailed history of Hudson Bay Capital Management LP transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Hudson Bay Capital Management LP holds 195,000 shares of RARE stock, worth $8.55 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
195,000
Previous 415,000 53.01%
Holding current value
$8.55 Million
Previous $17.1 Million 36.49%
% of portfolio
0.05%
Previous 0.09%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$40.21 - $59.36 $8.85 Million - $13.1 Million
-220,000 Reduced 53.01%
195,000 $10.8 Million
Q2 2024

Aug 14, 2024

BUY
$37.42 - $51.61 $4.11 Million - $5.67 Million
109,900 Added 36.02%
415,000 $17.1 Million
Q1 2024

May 15, 2024

SELL
$43.02 - $53.69 $7.95 Million - $9.93 Million
-184,900 Reduced 37.73%
305,100 $14.2 Million
Q4 2023

Feb 14, 2024

SELL
$31.73 - $49.19 $7.75 Million - $12 Million
-244,272 Reduced 33.27%
490,000 $23.4 Million
Q3 2023

Nov 14, 2023

BUY
$34.92 - $46.66 $8.12 Million - $10.8 Million
232,500 Added 46.34%
734,272 $26.2 Million
Q2 2023

Aug 14, 2023

SELL
$37.35 - $52.15 $2.61 Million - $3.65 Million
-70,000 Reduced 12.24%
501,772 $23.1 Million
Q1 2023

May 16, 2023

BUY
$36.99 - $48.71 $5.43 Million - $7.15 Million
146,706 Added 34.51%
571,772 $22.9 Million
Q1 2023

May 15, 2023

SELL
$36.99 - $48.71 $5.21 Million - $6.86 Million
-140,934 Reduced 24.9%
425,066 $17 Million
Q4 2022

Feb 14, 2023

BUY
$33.72 - $46.33 $7.62 Million - $10.5 Million
226,000 Added 66.47%
566,000 $26.2 Million
Q3 2022

Nov 14, 2022

BUY
$39.96 - $66.14 $9.95 Million - $16.5 Million
249,000 Added 273.63%
340,000 $14.1 Million
Q2 2022

Aug 12, 2022

BUY
$45.8 - $85.4 $4.17 Million - $7.77 Million
91,000 New
91,000 $5.43 Million
Q4 2020

Feb 12, 2021

SELL
$84.4 - $177.39 $2.53 Million - $5.32 Million
-30,000 Closed
0 $0
Q3 2020

Nov 12, 2020

SELL
$72.98 - $90.0 $7.66 Million - $9.45 Million
-105,000 Reduced 77.78%
30,000 $2.47 Million
Q2 2020

Aug 12, 2020

SELL
$46.91 - $78.22 $4.63 Million - $7.72 Million
-98,706 Reduced 42.24%
135,000 $10.6 Million
Q1 2020

May 14, 2020

SELL
$33.8 - $62.9 $1.9 Million - $3.54 Million
-56,294 Reduced 19.41%
233,706 $10.4 Million
Q4 2019

Feb 12, 2020

BUY
$36.08 - $45.83 $4.87 Million - $6.19 Million
135,000 Added 87.1%
290,000 $12.4 Million
Q3 2019

Nov 13, 2019

BUY
$42.5 - $63.11 $1.91 Million - $2.84 Million
45,000 Added 40.91%
155,000 $6.63 Million
Q1 2019

May 15, 2019

BUY
$39.87 - $69.36 $398,700 - $693,600
10,000 Added 10.0%
110,000 $7.63 Million
Q4 2018

Feb 13, 2019

BUY
$38.89 - $77.3 $3.89 Million - $7.73 Million
100,000 New
100,000 $4.35 Million
Q2 2018

Aug 13, 2018

SELL
$48.54 - $85.31 $5.82 Million - $10.2 Million
-120,000 Closed
0 $0
Q1 2018

May 14, 2018

BUY
$44.33 - $58.52 $886,600 - $1.17 Million
20,000 Added 20.0%
120,000 $6.12 Million
Q4 2017

Feb 12, 2018

BUY
$43.54 - $57.32 $4.35 Million - $5.73 Million
100,000
100,000 $4.64 Million

Others Institutions Holding RARE

About Ultragenyx Pharmaceutical Inc.


  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $3.07B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Hudson Bay Capital Management LP Portfolio

Follow Hudson Bay Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Hudson Bay Capital Management LP with notifications on news.